Precigen (PGEN) Income from Non-Controlling Interests (2012 - 2019)
Precigen (PGEN) posted quarterly Income from Non-Controlling Interests of -$165000.0 for Q2 2019, up 88.6% year-over-year from -$87488.1 in Q2 2018, and up 88.44% quarter-over-quarter from -$1.4 million in Q1 2019.
Powered by 
Analysis
Precigen (PGEN) Income from Non-Controlling Interests (2012 - 2019) Analysis & Trends
Precigen (PGEN) has reported Income from Non-Controlling Interests for 8 consecutive years, with -$165000.0 the latest figure, recorded in Q2 2019.
- In Q2 2019, Income from Non-Controlling Interests rose 88.6% year-over-year to -$165000.0; the TTM figure through Mar 2020 stood at -$165000.0 (up 97.03% YoY), while the FY2019 annual figure was -$1.6 million, up 70.35% from the prior year.
- Income from Non-Controlling Interests rose to -$165000.0 in Q2 2019 per PGEN's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$165000.0 in Q2 2019 and bottomed at -$6.7 million in Q4 2017.
- Historically, Income from Non-Controlling Interests has averaged -$1.3 million across 5 years, with a median of -$1.0 million in 2016.
- Annual changes were most pronounced in 2017 — Income from Non-Controlling Interests plunged 761.81% — and 2019, when it jumped 88.6%.
- Precigen's Income from Non-Controlling Interests stood at -$561000.0 in 2015, then sank by 38.15% to -$775000.0 in 2016, then plunged by 761.81% to -$6.7 million in 2017, then soared by 81.18% to -$1.3 million in 2018, then jumped by 86.87% to -$165000.0 in 2019.
- Business Quant data shows PGEN's Income from Non-Controlling Interests at -$165000.0 in Q2 2019, -$1.4 million in Q1 2019, and -$1.3 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | -165,000.00 |
| Mar 31, 2019 | -1.43 Mn |
| Dec 31, 2018 | -1.26 Mn |
| Sep 30, 2018 | -1.42 Mn |
| Jun 30, 2018 | -1.45 Mn |
| Mar 31, 2018 | -1.24 Mn |
| Dec 31, 2017 | -6.68 Mn |
| Sep 30, 2017 | -1.15 Mn |
| Jun 30, 2017 | -998,000.00 |
| Mar 31, 2017 | -978,000.00 |
| Dec 31, 2016 | -775,000.00 |
| Sep 30, 2016 | -1.03 Mn |
| Jun 30, 2016 | -967,000.00 |
| Mar 31, 2016 | -891,000.00 |
| Dec 31, 2015 | -561,000.00 |
| Sep 30, 2015 | -816,000.00 |
| Jun 30, 2015 | -831,000.00 |
| Mar 31, 2015 | -1.29 Mn |
| Dec 31, 2014 | -899,000.00 |
| Sep 30, 2014 | -1.14 Mn |